This study is looking at how well people with stage II or III gastric (stomach) cancer respond to standard 5-FU-based adjuvant chemotherapy after surgery. Researchers are analyzing genetic information from tumor tissue to create a model that can predict who will benefit most from this treatment. The goal is to better understand why some patients respond well and others don't, which could help doctors make more informed decisions about your care. To join, you must have stage II or III gastric cancer, have had surgery, received 5-FU-based chemotherapy, and have tumor tissue available for analysis. The study is trying to enroll 329 participants, but its current status is unclear. Success for this study means developing a model that can accurately predict treatment response based on whether cancer returns within three years after surgery.

Study design

This is an observational study, meaning no new treatments are given. Researchers are studying existing patient data and tissue samples.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants' treatment response will be measured at 3 years after surgery to see if their cancer has returned.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.